Treatment of iris melanoma and secondary neovascular glaucoma using bevacizumab and plaque radiotherapy

Archives of Ophthalmology

Volumn 126, Issue 4, 2008, Pages 578-579

  Bianciotto, Carlos ^b   Shields, Carol L ^a   Kang, Brian ^b   Shields, Jerry A ^b  

^a WILLS EYE HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ANAMNESIS; ASPIRATION BIOPSY; BIOMICROSCOPY; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME 3 MONOSOMY; DISEASE ASSOCIATION; GENETIC ANALYSIS; GONIOSCOPY; HUMAN; INTRAOCULAR PRESSURE; IRIS MELANOMA; LETTER; MALE; MICROARRAY ANALYSIS; MONOSOMY; NEOVASCULAR GLAUCOMA; OPHTHALMOSCOPY; PATIENT REFERRAL; PRIORITY JOURNAL; SLIT LAMP; TREATMENT OUTCOME; UVEA MELANOMA; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRACHYTHERAPY; COMBINED MODALITY THERAPY; GLAUCOMA, NEOVASCULAR; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; IRIS NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42249089310     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.4.578     Document Type: Letter

References (8)

1. Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology. 2001;108(1):172-178.
2. Shields CL, Materin MA, Shields JA, Gershenbaum E, Singh AD, Smith A. Factors associated with elevated intraocular pressure in eyes with iris melanoma. Br J Ophthalmol. 2001;85(6):666-669.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
4. Lee ES, Baratz KH, Pulido JS, Salomao DR. Expression of vascular endothelial growth factor in iris melanoma. Arch Ophthalmol. 2006;124(9):1349-1350.
5. Sahin A, Kiratli H, Tezel GG, Soylemezoglu F, Bilgic S. Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas. Ophthalmic Res. 2007;39(1):40-44.
6. Hurwitz H, Fehrenbacher J, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
7. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma [published online ahead of print May 30, 2007]. Ann Surg Oncol. 2007;14(8):2367-2376.
8. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26(3):354-356.